TMCnet News
Research and Markets: 2013 Report on the International Acute Myeloid Leukemia (AML) Market - Opportunity Analysis and Forecasts to 2017DUBLIN --(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/research/5g6pvq/opportunityanalyze) has announced the addition of the "2013 Report on the International Acute Myeloid Leukemia (AML) Market - Opportunity Analysis and Forecasts to 2017" report to their offering. Acute myeloid (myelogenous, myelocytic) leukemia is a rapidly progressing blood cancer with a poor overall prognosis. AML is relatively rare, and predominantly affects older adults. AML is a heterogeneous disease, and many subtypes have been identified. The current standard of care consists of cytarabine-based chemotherapy, which can often achieve remission. However, th majority of patients relapse, and survival rates are grim. There are clear unmet needs for treatments that can prolong the overall survival of these patients, but drug manufacturers have struggled to gain regulatory approval for new therapies. Key Questions Answered
Key Topics Covered: 1 List of Tables and Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Current Treatment Options 7 Unmet Needs Assessment and Opportunity Analysis 8 R&D Strategies 9 Pipeline Assessment 10 Pipeline Valuation Analysis 11 Appendix For more information visit http://www.researchandmarkets.com/research/5g6pvq/opportunityanalyze
|